Scrip 100: Robust M&A momentum continues to build
This article was originally published in Scrip
Executive Summary
Merger & acquisition (M&A) activity among pharmaceutical and bioscience companies has shown no signs of slowing down. More importantly, even though AstraZeneca's rejection of Pfizer's $120bn plus takeover overture has meant that 2014 cannot boast the largest ever M&A deal, the number of $10bn transactions this year has still surpassed that of 2012 and 2013.